12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

• Delcath Systems DCTH stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out today.
• Harrow HROW stock rose 32.64% to $16.01. The company's market cap stands at $566.4 million. As per the press release, Q1 earnings came out yesterday.
• ProKidney PROK shares moved upwards by 26.29% to $3.89. The company's market cap stands at $248.6 million. As per the news, the Q1 earnings report came out 2 days ago.
• Sunshine Biopharma SBFM stock rose 25.14% to $1.09. The market value of their outstanding shares is at $1.0 million.
• Pacific Biosciences PACB stock moved upwards by 22.02% to $2.35. The company's market cap stands at $641.3 million. As per the press release, Q1 earnings came out 3 days ago.
• Generation Bio GBIO stock rose 20.77% to $3.43. The market value of their outstanding shares is at $228.0 million. As per the press release, Q1 earnings came out yesterday.

Losers

• Scorpius Holdings SCPX stock declined by 52.1% to $0.09 during Tuesday's regular session. The company's market cap stands at $3.1 million.
• Augmedix AUGX shares declined by 50.0% to $1.17. The market value of their outstanding shares is at $57.2 million. As per the press release, Q1 earnings came out yesterday.
• Inotiv NOTV stock declined by 48.09% to $2.17. The company's market cap stands at $55.8 million.
• Akoya Biosciences AKYA stock decreased by 31.44% to $2.83. The company's market cap stands at $139.4 million. As per the press release, Q1 earnings came out yesterday.
• Virpax Pharmaceuticals VRPX shares declined by 18.1% to $2.49. The company's market cap stands at $2.9 million. The company's, Q1 earnings came out yesterday.
• Biolase BIOL stock declined by 16.81% to $0.15. The market value of their outstanding shares is at $5.0 million. As per the press release, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.